Next-Level Compliance: What Every Board Member Should Know

Fabiana Lacerca-Allen, President, Ethiprax

This article is geared towards members of Boards of Directors, C-level company leadership, and compliance professionals who recognize the need to continually improve compliance. Why is it important to drive compliance performance to the next level? It is vital, because status quo performance in a rapidly evolving global environment earns a failing mark. If your company is not adapting, if it does not have ethical leaders in the right places setting the right ethical “tone at the top,” the compliance program is not as robust as it should be and the company is likely carrying more compliance-related risk than it should.

Read full paper Subscribe to the IICJ
USA Compliance Consultant October 2016 Vol.10, No. 37, Autumn 2016

Fabiana Lacerca-Allen

More

M. Fabiana Lacerca-Allen has had more than 20 years of experience working for leading American companies such as Elan, Mylan, Bristol-Myers Squibb Company, Microsoft, Merck and AT&T. She has counseled and litigated in the field of international business transactions and international environment law. She has extensive experience in the pharmaceutical industry in leadership roles in charge of legal and compliance teams. She has counseled and represented clients in a broad range of questions, including strategic business initiatives ensuring compliance with laws and regulations, and corporate policy. Ms. Lacerca-Allen has provided legal support and strategic advice on opportunities and trends in law particularly within the government sector as well as with major and strategic corporate accounts. Fabiana has established policies and oversight on key areas of compliance affecting internationals markets and she has been able to positively impact the perception of compliance creating compliance training programs and relevant standard operating procedures and has been involved in validating and aiding due diligence in the compliance industry. frequently requested as speaker and participant in forum. Recognized in the industry by Hispanic Executive Magazine in 2013, http://hispanicexecutive.com/2013/fabiana-lacerca-allen/; a theguardian, recognized as 2015 Women in Leadership, Inspiring Leaders: http://www.theguardian.com/women-in-leadership/2015/may/12/know-who-you-want-to be-kidnapped-with-and-four-more-tips-for-leaders; served as Chair to the Bay Area Ethics & Compliance Association (BECA); and, served as Co Chair for CBI, an Advanstar company serving the Life Sciences industry. Ms. Lacerca-Allen was invited to join the Gioja Research Institute while she was a student researching on environmental law. She was recipient of 1992 UCLA’s tuition waiver based on merit and recognition, and she represented UCLA in the Roscoe Foundation National Essay Contest submitting a paper on Global Warming.

Ethiprax

More

Elan Drug Technologies (EDT) is the world’s leading drug delivery company and is a business unit of Elan (NYSE:ELN). As a fully integrated drug delivery business, we deliver clinically meaningful benefits to patients, by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products.

USA Compliance Consultant October 2016 Vol.10, No. 37, Autumn 2016

© International In-House Counsel Journal. ISSN 1754-0607. All rights reserved. Registered in England Company Number: 6187841. VAT Registration Number: 946 7381 82. | Terms & Conditions .